Barclays Starts Coverage on Editas Medicine, Inc. (EDIT) With A Rating Of “Overweight” – First News 24
Key Gazette |
Barclays Starts Coverage on Editas Medicine, Inc. (EDIT) With A Rating Of “Overweight”
First News 24 CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella and Francisella 1), bound to a guide RNA molecule designed to recognize a particular … Editas Medicine, Inc. (NASDAQ:EDIT) Closed 6.5% Above Its 50 …HugoPress |
Genetic Engineering & Biotechnology News (press release) |
“Good” Gut Bacteria Linked to Melanoma Immunotherapy Response
Genetic Engineering & Biotechnology News (press release) Scientists have uncovered a link between an individual’s gut bacteria and their response to anticancer immune checkpoint inhibitor therapy (ICT). A team of researchers at the Harold C. Simmons Comprehensive Cancer Center in Texas carried out what they … |
Genetic Engineering & Biotechnology News (press release) |
“Good” Gut Bacteria Linked to Melanoma Immunotherapy Response
Genetic Engineering & Biotechnology News (press release) Scientists have uncovered a link between an individual’s gut bacteria and their response to anticancer immune checkpoint inhibitor therapy (ICT). A team of researchers at the Harold C. Simmons Comprehensive Cancer Center in Texas carried out what they … |
|
Virus-specific T cells attack infections after hematopoietic stem cell transplantation
Healio An “off-the-shelf” approach using virus-directed virus-specific T cells safely and effectively treated patients with severe viral infections following allogeneic hematopoietic stem cell transplantation, according to phase 2 trial results published in … |
|
Human Gut Microbiome Linked with Response to Cancer Immunotherapy
Genetic Engineering & Biotechnology News Scientists have identified a link between an individual’s gut bacteria and their likely response to anticancer immune checkpoint inhibitor therapy (ICT). A team of researchers at the Harold C. Simmons Comprehensive Cancer Center in Texas carried out … |
Rare Disease Report |
Gene Therapy for HD Gets FDA Orphan Designation
Rare Disease Report uniQure N.V., the company that developed the first-ever approved gene therapy (for familial chylomicronemia syndrome), announced that the U.S. Food and Drug Administration (FDA) has now granted an Orphan Drug Designation for its gene therapy … uniQure Announces FDA Orphan Drug Designation for AMT-130 in Huntington’s disease~ First Investigational Gene …Markets Insider uniQure (QURE) Granted FDA Orphan Drug Designation for AMT-130 in Huntington’s DiseaseStreetInsider.com |